FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224255007> ?p ?o ?g. }

• W4224255007 endingPage "e227722" @default.
• W4224255007 startingPage "e227722" @default.
• W4224255007 abstract "<h3>Importance</h3> Neurologic adverse events (NAEs) due to immune checkpoint inhibitors (ICIs) can be fatal but are underexplored. <h3>Objective</h3> To compare NAEs reported in randomized clinical trials (RCTs) of US Food and Drug Administration–approved ICIs with other forms of chemotherapy and placebo. <h3>Data Sources</h3> Bibliographic databases (Embase, Ovid, MEDLINE, and Scopus data) and trial registries (ClinicalTrials.gov) were searched from inception through March 1, 2020. <h3>Study Selection</h3> Phase II/III RCTs evaluating the use of ICIs were eligible for inclusion. Unpublished trials were excluded from the analysis. <h3>Data Extraction and Synthesis</h3> Two investigators independently performed screening of trials using the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guideline. NAEs were recorded for each arm. Data were pooled using a random-effects model. <h3>Main Outcomes and Measures</h3> The risk of NAEs with ICI use compared with any drug regimen, cytotoxic chemotherapy, and placebo. <h3>Results</h3> A total 39 trials including 23 705 patients were analyzed (16 135 [68.0%] men, 7866 [33.1%] White). The overall risk of a NAE was lower in the ICI group (risk ratio [RR], 0.59; 95% CI, 0.45-0.77) and in the subgroup of RCTs comparing ICI use with chemotherapy (RR, 0.22; 95% CI, 0.13-0.39). In the subgroup of RCTs comparing ICI with placebo, the overall risk of NAE was significantly higher in the ICI group (RR, 1.57; 95% CI, 1.30-1.89). Peripheral neuropathy (RR, 0.30; 95% CI, 0.17-0.51) and dysgeusia (RR, 0.41; 95% CI, 0.27-0.63) were significantly lower in the ICI group. Headache was more common with the use of ICIs (RR, 1.32; 95% CI, 1.10-1.59). In the subgroup analysis of RCTs comparing ICI use with chemotherapy, peripheral neuropathy (RR, 0.09; 95% CI, 0.05-0.17), dysgeusia (RR, 0.42; 95% CI, 0.21-0.85), and paresthesia (RR, 0.29; 95% CI, 0.13-0.67) were significantly lower in the ICI group. RCTs comparing ICIs with placebo showed a higher risk of headache with ICI use (RR, 1.63; 95%, CI, 1.32-2.02). <h3>Conclusions and Relevance</h3> Results of this meta-analysis suggest that the overall risk of NAEs, peripheral neuropathy, and dysgeusia is lower with the use of ICI. When compared with chemotherapy, the overall risk of NAE, peripheral neuropathy, paresthesia, and dysgeusia was lower with ICI use; however, when compared with placebo, the risk of NAEs is higher with the use of ICI." @default.
• W4224255007 created "2022-04-26" @default.
• W4224255007 creator A5024913531 @default.
• W4224255007 creator A5028547710 @default.
• W4224255007 creator A5029565453 @default.
• W4224255007 creator A5040467547 @default.
• W4224255007 creator A5041529923 @default.
• W4224255007 creator A5059061070 @default.
• W4224255007 creator A5061961350 @default.
• W4224255007 creator A5072855131 @default.
• W4224255007 creator A5080354454 @default.
• W4224255007 date "2022-04-19" @default.
• W4224255007 modified "2023-10-01" @default.
• W4224255007 title "Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events" @default.
• W4224255007 cites W1979811833 @default.
• W4224255007 cites W1989717470 @default.
• W4224255007 cites W1992820423 @default.
• W4224255007 cites W2021593215 @default.
• W4224255007 cites W2070825440 @default.
• W4224255007 cites W2097995306 @default.
• W4224255007 cites W2098923148 @default.
• W4224255007 cites W2104347254 @default.
• W4224255007 cites W2114011456 @default.
• W4224255007 cites W2114458368 @default.
• W4224255007 cites W2123363005 @default.
• W4224255007 cites W2134833483 @default.
• W4224255007 cites W2141080067 @default.
• W4224255007 cites W2155599713 @default.
• W4224255007 cites W2198093519 @default.
• W4224255007 cites W2222086386 @default.
• W4224255007 cites W2293531514 @default.
• W4224255007 cites W2338423971 @default.
• W4224255007 cites W2480201404 @default.
• W4224255007 cites W2527905628 @default.
• W4224255007 cites W2529484692 @default.
• W4224255007 cites W2529904548 @default.
• W4224255007 cites W2532352313 @default.
• W4224255007 cites W2560367415 @default.
• W4224255007 cites W2567564314 @default.
• W4224255007 cites W2569887568 @default.
• W4224255007 cites W2572174216 @default.
• W4224255007 cites W2588681363 @default.
• W4224255007 cites W2588916311 @default.
• W4224255007 cites W2591766135 @default.
• W4224255007 cites W2612010935 @default.
• W4224255007 cites W2635951006 @default.
• W4224255007 cites W2725487442 @default.
• W4224255007 cites W2734373861 @default.
• W4224255007 cites W2753529762 @default.
• W4224255007 cites W2756666776 @default.
• W4224255007 cites W2766729634 @default.
• W4224255007 cites W2768429453 @default.
• W4224255007 cites W2777192533 @default.
• W4224255007 cites W2796582438 @default.
• W4224255007 cites W2797309423 @default.
• W4224255007 cites W2806614796 @default.
• W4224255007 cites W2883552436 @default.
• W4224255007 cites W2886160778 @default.
• W4224255007 cites W2890965651 @default.
• W4224255007 cites W2891486030 @default.
• W4224255007 cites W2892640821 @default.
• W4224255007 cites W2893602866 @default.
• W4224255007 cites W2893824814 @default.
• W4224255007 cites W2893960509 @default.
• W4224255007 cites W2903493423 @default.
• W4224255007 cites W2911455769 @default.
• W4224255007 cites W2912107322 @default.
• W4224255007 cites W2913745075 @default.
• W4224255007 cites W2925446385 @default.
• W4224255007 cites W2938645074 @default.
• W4224255007 cites W2943887705 @default.
• W4224255007 cites W2946386783 @default.
• W4224255007 cites W2947945944 @default.
• W4224255007 cites W2956888684 @default.
• W4224255007 cites W2962324833 @default.
• W4224255007 cites W2966241727 @default.
• W4224255007 cites W2967350775 @default.
• W4224255007 cites W2991309441 @default.
• W4224255007 cites W3003670850 @default.
• W4224255007 cites W3045946240 @default.
• W4224255007 cites W3132753816 @default.
• W4224255007 cites W4249524274 @default.
• W4224255007 cites W49248409 @default.
• W4224255007 doi "https://doi.org/10.1001/jamanetworkopen.2022.7722" @default.
• W4224255007 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35438755" @default.
• W4224255007 hasPublicationYear "2022" @default.
• W4224255007 type Work @default.
• W4224255007 citedByCount "15" @default.
• W4224255007 countsByYear W42242550072022 @default.
• W4224255007 countsByYear W42242550072023 @default.
• W4224255007 crossrefType "journal-article" @default.
• W4224255007 hasAuthorship W4224255007A5024913531 @default.
• W4224255007 hasAuthorship W4224255007A5028547710 @default.
• W4224255007 hasAuthorship W4224255007A5029565453 @default.
• W4224255007 hasAuthorship W4224255007A5040467547 @default.
• W4224255007 hasAuthorship W4224255007A5041529923 @default.
• W4224255007 hasAuthorship W4224255007A5059061070 @default.
• W4224255007 hasAuthorship W4224255007A5061961350 @default.

• next